Logo-bi
Original Research
Fatemeh Khonsari ORCID, Mostafa Heydari ORCID, Rassoul Dinarvand ORCID, Mohammad Sharifzadeh ORCID, Fatemeh Atyabi* ORCID
Bioimpacts. 2022;12(1): 21-32. doi: 10.34172/bi.2021.23389
PMCID: PMC8783081     PMID: 35087713     Scopus ID: 85127207881    
Nanostructured-Lipid-Carriers (NLCs) for brain delivery of rapamycin were designed by modification of optimized cationic-NLCs (C-NLC) with different approaches. The targeted transferrin decorated NLCs(Tf-NLCs) in comparison to untargeted bare-NLCs (B-NLCs) showed higher cellular uptake and appropriate targeted accumulation in the brain.
Original Article
Yuri Yu. Shchegolev ORCID, Danila V. Sorokin, Alexander M. Scherbakov* ORCID, Olga E. Andreeva ORCID, Diana I. Salnikova ORCID, Ekaterina I. Mikhaevich ORCID, Margarita V. Gudkova ORCID, Mikhail A. Krasil’nikov ORCID
Bioimpacts. 2023;13(4): 313-321. doi: 10.34172/bi.2023.27490
PMCID: PMC10460766     PMID: 37645026     Scopus ID: 85168127787    
Prolonged cell treatment with mTOR inhibitor rapamycin leads to the development of resistance. Exosomes of resistant cells induce the resistance to rapamycin in the parent MCF-7cells. Exosome-induced resistance reproduces the changes revealed in the rapamycin-resistant cells, including the activation of ERK/AP-1.
Original Article
Fateme Arjmand ORCID, Samaneh Shojaei, Mitra Khalili, Hossein Dinmohammadi, Behzad Poopak, Samira Mohammadi-Yeganeh* ORCID, Yousef Mortazavi* ORCID
Bioimpacts. 2024;14(4): 28870. doi: 10.34172/bi.2023.28870
PMCID: PMC11298021     PMID: 39104620    


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge